About The Report
The global coronary stents sector is on track to achieve a valuation of USD 64.6 billion by 2036, accelerating from USD 37.5 billion in 2026 at a CAGR of 5.6%. As per Future Market Insights, expansion is structurally underpinned by the persistent global burden of coronary artery disease and the continuous refinement of percutaneous coronary intervention (PCI) techniques. The World Health Organization reported in 2024 that cardiovascular diseases remain the leading cause of death globally, accounting for approximately 17.9 million deaths annually, which validates the structural demand for coronary revascularization devices. This disease burden compels interventional cardiology device manufacturers to invest in both next-generation drug-eluting platforms and bioresorbable scaffold technologies. Simultaneously, the regulatory landscape is shifting from first-generation DES benchmarks to more stringent clinical endpoint requirements for new stent approvals, which forces longer and more complex clinical trial programs.
Mike Mahoney, Chairman and CEO of Boston Scientific, stated: '2025 was another exceptional year for Boston Scientific, with our global teams delivering differentiated innovation and high performance that enabled us to exceed our goals.' This broad performance is reflected in the company's interventional cardiology division, which continues to hold a leading position in the global DES market. In May 2024, Abbott launched its latest-generation XIENCE Sierra drug-eluting stent in India, featuring an ultra-low profile and high-flexibility delivery system engineered to treat complex coronary anatomies including multi-vessel blockages and chronic total occlusions. FMI opines that Abbott's India launch is indicative of the broader trend where device companies prioritize high-volume emerging markets for new product introductions, capitalizing on both growing procedural volumes and favorable regulatory timelines.
The operational reality for coronary stent suppliers is defined by the need to balance the clinical promise of bioresorbable scaffolds with the proven long-term track record of metallic DES platforms. In September 2025, MicroPort launched Firesorb, its next-generation bioresorbable vascular scaffold (BVS), following successful multi-year clinical follow-ups in the FUTURE study series. Brian Chang, Chief Medical Officer at MicroPort, stated: 'Being named a landmark study alongside other pivotal trials demonstrates the study's potential to change clinical practice and improve outcomes for patients worldwide.' As per FMI, the Firesorb launch is the most significant bioresorbable scaffold commercialization since the withdrawal of Abbott's Absorb BVS, and its clinical trajectory will determine whether the bioresorbable category can reclaim clinician confidence. The scaffold is designed to support the vessel during the healing phase and then naturally dissolve, leaving the artery free of permanent foreign material.
Future Market Insights projects the coronary stents market to expand at a CAGR of 5.6% from 2026 to 2036, increasing from USD 37.5 Billion in 2026 to USD 64.6 Billion by 2036.
FMI Research Approach: FMI proprietary forecasting model based on PCI procedure volumes and DES/BVS adoption rates.
FMI analysts perceive the market evolving toward a dual-platform structure where established metallic DES systems continue as the high-volume standard while bioresorbable scaffolds gain share in select complex lesion applications.
FMI Research Approach: MicroPort Firesorb BVS launch (September 2025) and Abbott XIENCE Sierra clinical data.
The United States holds a significant share of the global coronary stents market by value, which is supported by the highest per-capita PCI procedural rate and premium reimbursement for next-generation DES platforms.
FMI Research Approach: FMI country-level revenue modeling by PCI procedure volumes and CMS reimbursement rates.
The global coronary stents market is projected to reach USD 64.6 Billion by 2036.
FMI Research Approach: FMI long-term revenue forecast derived from WHO cardiovascular disease burden projections and PCI volume growth rates.
The coronary stents market includes revenue from drug-eluting stents (DES), bare-metal stents (BMS), and bioresorbable vascular scaffolds (BVS) used in percutaneous coronary intervention procedures for coronary artery disease treatment.
FMI Research Approach: FMI market taxonomy aligned with FDA and CE-mark device classifications.
Globally unique trends include the re-emergence of bioresorbable scaffold technology with improved clinical outcomes, the launch of ultra-low-profile DES platforms for complex anatomies, and the prioritization of emerging markets for new stent introductions.
FMI Research Approach: MicroPort Firesorb launch (September 2025) and Abbott XIENCE Sierra India launch (May 2024).
| Metric | Details |
|---|---|
| Industry Size (2026) | USD 37.5 Billion |
| Industry Value (2036) | USD 64.6 Billion |
| CAGR (2026 to 2036) | 5.6% |
Source: Future Market Insights (FMI) analysis, based on proprietary forecasting model and primary research
| Attributes | Details |
|---|---|
| Top Source Type | Drug-Eluting Stents (DES) |
| Market Share in 2025 | 33.2% |
Drug-eluting stents (DES) is expected to account for a leading coronary stent market share of 33.2% in 2025. The Drug Eluting Stent has the capability to prevent the risks of restenosis (the process of the arteries getting smaller again), which is known to be caused by scar tissue, and it does this by means of drugs that prevent the production of the scar tissue. The rise in coronary artery disease, which is a common health problem, has resulted in a demand for the newest stent technologies like DES. These particular types of stents perform better in challenging cases of surgery.
| Attributes | Details |
|---|---|
| Top Source Type | Hospitals |
| Market Share in 2025 | 27.1% |
Hospitals are poised to occupy 27.1% of the coronary stents market in 2025 due to the advanced clinical facilities. Hospitals, particularly the larger medical center types, are outfitted with the newest equipment and have specialized cardiology departments, therefore, they are the best choice for complex heart procedures.
On the other hand, the adoption of new technologies by manufacturing for stent models ensures the production of higher quality products while minimizing environmental impact, waste generation, energy consumption, and other costs. Hospitals primarily offer after-procedure care like dosage control, angiogram as a follow-up treatment, and lifestyle changes advice which together, help in the recovery of patients and also promote the stay of the stents in the bodies of the patients, especially in the healthcare systems that are good.
High Prevalence of Cardiovascular Diseases Pushes the Demand for Minimally Invasive Procedures
Cardiovascular diseases (CVDs) have become more common worldwide, and the need for coronary stents has grown exponentially, throughout the years of the pandemic. The predominant risk factors are poor diet, smoking, sedentary lifestyle, and stress. According to World Health Organization (WHO) CVDs are primarily responsible for premature deaths among the population with about 18 million fatalities every year.
The coronary stent sector is seeing technological progress with items like drug-eluting stents (DES) which are capable of discharging medicine meant to obstruct restenosis, biodegradable stents that erode after a certain period of time, and state-of-the-art imaging equipment like OCT (optical coherence tomography) which comes in handy for proper stent placement.
Technological Advancements in Stent Design Improves Patient Outcomes
Technological advancements in stent design are significantly improving patient outcomes. Drug-eluting stents (DES) release medication that prevents tissue overgrowth, reducing restenosis rates compared to traditional bare-metal stents. Bioabsorbable stents, which dissolve over time, offer the advantage of eliminating long-term complications.
Additionally, advanced coatings have improved biocompatibility and minimizes the risks of stent thrombosis. Healthcare providers have turned to coronary stents due to different innovations in the sector such as Drug Eluting Stents, Biodegradable Stents and Bioresorbable Vascular scaffolds which give higher effectivity and safety.
| Aspect | Details |
|---|---|
| Complex Regulations | Coronary stents are objects that are directly placed inside the human body. They are strictly bound to the safety and efficacy standards. From a regulatory aspect organizations such as FDA (USA), EMA (Europe), and CDSCO (India), underlines extensive clinical trials and tight testing to be conducted prior any approval. A manufacturer undergoing the approval period often faces a complex procedure that might negatively impact their market entry. |
| Cost of Compliance | Significant expenditure is involved in compliance with regulatory standards that often impacts the overall operations. It is imperative that production enterprises incur cost investments for research, clinical trials, and meet sustainability standards. The aforementioned factors may be the rationale for the high overall product price and postponement of the product launch. |
| Regional Variations | The cross-market strategies of companies are hampered by regional variances in disease prevalence, health care systems and economic factors thus rendering it harder for companies to implement the same strategies across the board. They have to tailor their products, pricing, and regulations to the requirements of every market. |
| Impact | The strict regulatory framework can slow innovation and limit the availability of new products. For smaller manufacturers, the barriers to entry can restrict competition, ultimately affecting the variety of treatment options available to patients. |
| Aspect | Details |
|---|---|
| Pricing Challenges | The pricing of state-of-the-art coronary stents, especially drug-eluting and bioabsorbable is on the higher side as they involve advanced technology and materials. These elevated prices make the products unaffordable thus, stents are inaccessible to many parts of the population, particularly in underdeveloped countries and even some middle-income countries. The costs involved can influence patient decision to choose stent therapies. |
| Reimbursement Limitations | Reimbursement restrictions manifested in the coronary stents market due to the existence of different healthcare policies in different areas, which frequently set restrictions on the use of high-cost stents like drug-eluting and biodegradable ones. These limitations cause patients to be dependent on cheaper bare-metal stents thus, affecting the market growth for CRT and innovative technologies. |
| Health Disparities | Rural or underserved spaces often lack access to high-end cardiac care including stent implantation. The deficit of adequate resources and capital is the main reason for the increased obstructions in healthcare in these areas. Hence, the population from such areas lack access to life-saving techniques leading to fatality from cardiovascular diseases. |
| Impact | The capacity of advanced cardiac care like stenting is very low in rural and underserved parts.. The absence of necessary facilities and qualified personnel in these parts is the major reason why healthcare disparities are so acute.. |
The increasing acceptance of bioabsorbable stents (also referred to as bioresorbable vascular scaffolds or BVS) is a notable trend. These state-of-the-art stents outperform conventional permanent stents in terms of dissolving cells over time, which results in no permanent implant in the body.
| Countries | CAGR |
|---|---|
| The USA | 1.5% |
| Canada | 2.7% |
| Germany | 1.6% |
| France | 2.4% |
| Italy | 2.9% |
| UK | 1.9% |
The USA dominates the coronary stents market with a sizeable share of global sales. Factors such as availability of an advanced medical care system and the high prevalence of cardiovascular diseases (CVDs) in the population. The popularity of drug-eluting and bioabsorbable stents is leading to high demand.
Abbott Laboratories and Boston Scientific are significantly invest in innovations in the field of high-technology drug-eluting stents, bioresorbable stents, and next-gen imaging devices, particularly. Abbott's Xience drug-eluting stent and Boston Scientific's Synergy stent are both, demonstrating the development methods for the leading-edge innovation of coronary stents.
Researchers and manufacturers are focusing on combining imaging, stent technology, and personalized medicine to improve outcomes. This includes developing advanced imaging tools for better stent placement and creating stents tailored to individual patient needs.
Europe is the fast-growing market thanks to its advanced healthcare system and a high rate of lifestyle-related health issues, Germany is leading the European coronary stents market. The government and the private companies are dedicated to improving medical devices through innovation by provide funding, resources, and incentives to support the development of new technologies in healthcare. Angioplasty and stent procedures are widely accessible through health insurance.
The coronary stent market has made impressive strides of progress throughout the past years in factors such as new product launches, market entrants, and the changing regulatory landscape.
Elunir-Perl Drug-Eluting Stent by Medinol
Elunir-Perl was FDA approved in October 2023 and is a new stent for coronary artery disease that is designed to provide patients with a safe and effective treatment.
Xience Sierra by Abbott Laboratories
Xience Sierra was FDA approved in 2018 and is a drug-eluting stent which features a lower profile and better flexibility and is produced in small diameters and longer lengths. It's meant to assist complex percutaneous coronary interventions (PCI), thus aiding in a better patient outcome.
Resolute Onyx 2.0mm by Medtronic
Resolute Onyx 2.0mm was FDA approved in 2018. It is a tiny drug-eluting stent that is made for patients with small coronary arteries thus making it more effective in treating the problems of patients with complicated anatomy.
Recent Developments
Emerging startups are driving the advancement of bioresorbable stent technology; they are now targeting next-generation solutions, which are the ones that naturally dissolve in the body; this way, there is no need for permanent implants. These stents are a safe alternative to metal stents as they prevent complications like late stent thrombosis and are actually safer than traditional metal stents. A few notable companies in the field include:
The coronary stents market represents revenue generated from implantable coronary artery stents and scaffolds used in percutaneous coronary intervention (PCI) procedures. The market measures the value of drug-eluting stents, bare-metal stents, and bioresorbable vascular scaffolds sold to hospitals, catheterization laboratories, and interventional cardiology centers.
Inclusions cover drug-eluting stents (polymer-coated and polymer-free), bare-metal stents, bioresorbable vascular scaffolds, and dual-therapy stents. It includes balloon-expandable and self-expanding delivery systems. Dedicated PCI guidewires and inflation devices bundled with stent systems are also included.
Exclusions include peripheral vascular stents, carotid stents, structural heart devices such as TAVR valves, and standalone PCI diagnostic equipment. Coronary artery bypass graft (CABG) surgical instruments and standalone angiography systems are outside the scope.
| Items | Values |
|---|---|
| Quantitative Units (2026) | USD 37.5 Billion |
| Product Type | Drug-Eluting Stents, Bare-Metal Stents, Bioresorbable Vascular Scaffolds |
| Material Type | Cobalt-Chromium, Platinum-Chromium, Stainless Steel, PLLA Bioresorbable |
| End User | Hospitals, Catheterization Laboratories, Interventional Cardiology Centers |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Key Companies Profiled | Boston Scientific, Abbott, Medtronic, MicroPort, B. Braun, Terumo |
Drug Eluting Stents (DES), Bare Metal Stents (BMS), Bioabsorbable Stents, Self-expanding Stents, Balloon-expandable Stents, etc.
Hospitals, Cardiac Centers, Ambulatory Surgical Centers, and Other Healthcare Settings.
Cobalt-Chromium, Stainless Steel, Platinum-Chromium, Nickel-Titanium, Polymer
North America, Latin America, Western Europe, South Asia and Pacific, East Asia, Middle East and Africa.
The global market is valued at USD 37.5 Billion in 2026, driven by the persistent global cardiovascular disease burden and advancing DES and BVS technologies.
The market is projected to grow at a CAGR of 5.6% from 2026 to 2036.
Asia Pacific leads due to rapidly growing PCI procedure volumes in India and China, followed by North America driven by premium DES reimbursement and BVS clinical adoption.
The re-emergence of clinically validated bioresorbable scaffolds and the launch of ultra-low-profile DES platforms for complex lesions are the primary growth catalysts.
Boston Scientific, Abbott, Medtronic, and MicroPort are key players, differentiating through next-generation DES delivery systems and bioresorbable scaffold technology.
Our Research Products
The "Full Research Suite" delivers actionable market intel, deep dives on markets or technologies, so clients act faster, cut risk, and unlock growth.
The Leaderboard benchmarks and ranks top vendors, classifying them as Established Leaders, Leading Challengers, or Disruptors & Challengers.
Locates where complements amplify value and substitutes erode it, forecasting net impact by horizon
We deliver granular, decision-grade intel: market sizing, 5-year forecasts, pricing, adoption, usage, revenue, and operational KPIs—plus competitor tracking, regulation, and value chains—across 60 countries broadly.
Spot the shifts before they hit your P&L. We track inflection points, adoption curves, pricing moves, and ecosystem plays to show where demand is heading, why it is changing, and what to do next across high-growth markets and disruptive tech
Real-time reads of user behavior. We track shifting priorities, perceptions of today’s and next-gen services, and provider experience, then pace how fast tech moves from trial to adoption, blending buyer, consumer, and channel inputs with social signals (#WhySwitch, #UX).
Partner with our analyst team to build a custom report designed around your business priorities. From analysing market trends to assessing competitors or crafting bespoke datasets, we tailor insights to your needs.
Supplier Intelligence
Discovery & Profiling
Capacity & Footprint
Performance & Risk
Compliance & Governance
Commercial Readiness
Who Supplies Whom
Scorecards & Shortlists
Playbooks & Docs
Category Intelligence
Definition & Scope
Demand & Use Cases
Cost Drivers
Market Structure
Supply Chain Map
Trade & Policy
Operating Norms
Deliverables
Buyer Intelligence
Account Basics
Spend & Scope
Procurement Model
Vendor Requirements
Terms & Policies
Entry Strategy
Pain Points & Triggers
Outputs
Pricing Analysis
Benchmarks
Trends
Should-Cost
Indexation
Landed Cost
Commercial Terms
Deliverables
Brand Analysis
Positioning & Value Prop
Share & Presence
Customer Evidence
Go-to-Market
Digital & Reputation
Compliance & Trust
KPIs & Gaps
Outputs
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
Demand for Coronary Stents in Japan Size and Share Forecast Outlook 2025 to 2035
Demand for Coronary Stents in USA Size and Share Forecast Outlook 2025 to 2035
Coronary CT Angiography Software Market Size and Share Forecast Outlook 2026 to 2036
Coronary Artery Bypass Grafts Market Size and Share Forecast Outlook 2025 to 2035
Coronary Intravascular Lithotripsy Market Size and Share Forecast Outlook 2025 to 2035
Coronary Guidewires Market
Venous Stents Market Size and Share Forecast Outlook 2025 to 2035
Enteral Stents Market
Demand for Coronary Artery Bypass Graft in United Kingdom Size and Share Forecast Outlook 2026 to 2036
Demand for Coronary Artery Bypass Graft in South Korea Size and Share Forecast Outlook 2026 to 2036
Demand for Coronary Artery Bypass Graft in Japan Size and Share Forecast Outlook 2025 to 2035
Demand for Coronary Artery Bypass Graft in USA Size and Share Forecast Outlook 2025 to 2035
Nephrology Stents and Catheters Market
Non-Vascular Stents Market Growth - Trends & Forecast 2025 to 2035
Bioabsorbable Stents Market Growth – Trends & Forecast 2025 to 2035
Bioresorbable Coronary Scaffolds Market
Industrial Analysis of Coronary Stent in India Size and Share Forecast Outlook 2025 to 2035
Demand for Non-Vascular Stents in Japan Size and Share Forecast Outlook 2025 to 2035
Demand for Non-Vascular Stents in USA Size and Share Forecast Outlook 2025 to 2035
Coronary Stents Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
